Slide 1 Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative…

Slide 1 Presented By Christina Tsien at 2014 ASCO Annual Meeting Current Limitations in the Response Assessment of Anti-Angiogenic Therapy Presented By Christina Tsien at…

Slide 1 Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014…

Slide 1 Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff…

Slide 1 Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting Metastatic Cervical Cancer Presented By Christian Hinrichs at 2014 ASCO Annual Meeting Adoptive…

Slide 1 Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014…

Slide 1 Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff…

Slide 1 Lung Cancer:Whatâs New and Whatâs Old? Presented By Leora Horn at 2014 ASCO Annual Meeting Outline Slide Presented By Leora Horn at 2014 ASCO Annual Meeting Slide…